SURMOUNT-1: Tirzepatide 15 mg, the generational leap of 2022 SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) randomized 2,539 obese adults without diabetes to tirzepatide 5, 10, or 15 mg/week or placebo over 72 weeks
In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said that they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity
Drug interactions are relatively uncommon with GLP-1 receptor agonists, but their effect on gastric emptying can delay the absorption of oral medications
Together, weve lost over 200 pounds on a GLP-1
Medscape (2026) 12
Hydration and sun protection to prevent collagen degradation